ArticleClinical and translational radiation oncology2025
Biological sex representation and reporting in stereotactic body radiotherapy for kidney cancer: A review of clinical studies.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pan-cancer analysis of Notch pathway-linked gene expression identifies tumour-specific and sex-stratified prognostic associations.Clinical and translational radiation oncology · 2026Article
- Pan-Cancer profiling of ferroptosis-related genes reveals prognostic biomarkers and sex-specific associations.Clinical and translational radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) is evolving as treatment modality for kidney cancer alongside increased recognition of the importance of sex as a biological variable (SABV) policy in generating deeper insights. Purpose: This review aimed to assess the representation of male and female patients and the reporting of sex-specific outcomes in SBRT clinical studies for primary localised kidney cancer. Methodology: A database search with appropriate search terms was carried out on EMBASE, CINAHL, and Web of Science. Consideration of biological sex was assessed with the male: female ratio, reporting of sex-specific treatment outcomes, and inclusion of sex as a variable in univariate and/or multivariate analysis. Conclusion: Supporting the integration of SABV will promote more equitable and biologically informed evidence for the use of SBRT in the management of kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.